Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 3/2016

01-03-2016 | Nuclear Medicine

Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours

Authors: S. Van Binnebeek, B. Vanbilloen, K. Baete, C. Terwinghe, M. Koole, F. M. Mottaghy, P. M. Clement, L. Mortelmans, K. Bogaerts, K. Haustermans, K. Nackaerts, E. Van Cutsem, C. Verslype, A. Verbruggen, C. M. Deroose

Published in: European Radiology | Issue 3/2016

Login to get access

Abstract

Objectives

To compare the diagnostic accuracy of 111In-pentetreotide-scintigraphy with 68Ga-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality.

Methods

Fifty-three metastatic-NET-patients underwent 111In-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body 68Ga-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities.

Results

Significantly more lesions were detected on 68Ga-DOTATOC-PET/CT versus 111In-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1–105; median: 15) versus 660 on SPECT (range: 0–73, median: 9) (p<0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3–100.0), for SPECT 60.0 % (95 % CI, 48.5–70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton.

Conclusion

Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to 111In-pentetreotide SPECT.

Key Points

• Somatostatin receptor PET is superior to SPECT in detecting NET metastases
• PET is the scintigraphic method for accurate depiction of NET tumour burden
• The sensitivity of PET is twofold higher than the sensitivity of SPECT
Literature
1.
Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72CrossRefPubMed
2.
Reubi JC, Schar JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282CrossRefPubMed
3.
Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793CrossRefPubMed
4.
Kwekkeboom DJ, Kooij PP, Bakker WH et al (1999) Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 40:762–767PubMed
5.
Imhof A, Brunner P, Marincek N et al (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423CrossRefPubMed
6.
Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130CrossRefPubMed
7.
Hofmann M, Maecke H, Borner R et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751–1757CrossRefPubMed
8.
Kwekkeboom DJ, Krenning EP, Scheidhauer K et al (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 90:184–189CrossRefPubMed
9.
Haug AR, Cindea-Drimus R, Auernhammer CJ et al (2012) The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors. J Nucl Med 53:1686–1692CrossRefPubMed
10.
Koukouraki S, Strauss LG, Georgoulias V et al (2006) Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33:460–466CrossRefPubMed
11.
Teunissen JJ, Krenning EP, de Jong FH et al (2009) Effects of therapy with [177Lu-DOTA 0, Tyr 3]octreotate on endocrine function. Eur J Nucl Med Mol Imaging 36:1758–1766PubMedCentralCrossRefPubMed
12.
Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518CrossRefPubMed
13.
Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626CrossRefPubMed
14.
Srirajaskanthan R, Kayani I, Quigley AM et al (2010) The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51:875–882CrossRefPubMed
15.
van Essen M, Krenning EP, Kam BL et al (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5:382–393CrossRefPubMed
16.
Meyer GJ, Macke H, Schuhmacher J et al (2004) 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 31:1097–1104CrossRefPubMed
17.
Van Binnebeek S, Deroose CM, Baete K et al (2011) Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy. J Clin Oncol 29:e579–e581CrossRefPubMed
18.
Van Binnebeek S, Baete K, Terwinghe C et al (2013) Significant impact of transient deterioration of renal function on dosimetry in PRRT. Ann Nucl Med 27:74–77CrossRefPubMed
19.
Van Binnebeek S, Baete K, Vanbilloen B et al (2014) Individualized dosimetry-based activity reduction of (9)(0)Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 41:1141–1157PubMed
20.
Kowalski J, Henze M, Schuhmacher J et al (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42–48CrossRefPubMed
21.
Geijer H, Breimer LH (2013) Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 40:1770–1780CrossRefPubMed
22.
Treglia G, Castaldi P, Rindi G et al (2012) Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42:80–87CrossRefPubMed
23.
Schreiter NF, Brenner W, Nogami M et al (2012) Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39:72–82CrossRefPubMed
Metadata
Title
Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
Authors
S. Van Binnebeek
B. Vanbilloen
K. Baete
C. Terwinghe
M. Koole
F. M. Mottaghy
P. M. Clement
L. Mortelmans
K. Bogaerts
K. Haustermans
K. Nackaerts
E. Van Cutsem
C. Verslype
A. Verbruggen
C. M. Deroose
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 3/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-3882-1

Other articles of this Issue 3/2016

European Radiology 3/2016 Go to the issue

Interventional

Intraprocedural blood volume measurement using C-arm CT as a predictor for treatment response of malignant liver tumours undergoing repetitive transarterial chemoembolization (TACE)

Head and Neck

Clinical significance of three-dimensional measurement of tumour thickness on magnetic resonance imaging in patients with oral tongue squamous cell carcinoma

Cardiac

Image quality, radiation dose, and diagnostic accuracy of prospectively ECG-triggered high-pitch coronary CT angiography at 70 kVp in a clinical setting: comparison with invasive coronary angiography

Musculoskeletal

Correlation of force control with regional spinal DTI in patients with cervical spondylosis without signs of spinal cord injury on conventional MRI

Computed Tomography

An appraisal of the computed axial tomographic appearance of the human mesentery based on mesenteric contiguity from the duodenojejunal flexure to the mesorectal level

Interventional

Meralgia paraesthetica: Ultrasound-guided injection at multiple levels with 12-month follow-up